Dr. Chilukuri will aid product development and oversee all clinical research protocols.

Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. 

In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinical research protocols as the lead investigator in upcoming clinical studies.

"When I was introduced to Hydrinity I was immediately impressed. It's a true advancement in hyaluronic acid technology and products, something we haven't seen in the market for 20 years," says Dr. Chilukuri, in a news release. "I look forward to being a part of the brand's future innovations they bring to the professional skincare market, as well as growing the brand's Medical Advisory Board and overseeing their clinical studies." 

"We are thrilled to welcome Dr. Chilukuri to the Hydrinity team as our Chief Medical Advisor," says Keith O'Briant, CEO of Hydrinity Accelerated Skin Science. "With deep roots in regenerative medicine, we know our partnership with Dr. Chilukuri will strengthen our mission to innovate and disrupt the cosmeceutical skincare space with industry leading products and technology."

In 2022, Hydrinity introduced the next generation of hyaluronic acid (HA) to the aesthetics industry utilizing a patented extraction process that creates a 99.9% pure, injectable grade HA molecule in two precise weights. The HA is combined with other proprietary technologies from the brand, including PPM6 Technology.